2024-09-24 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops, manufactures, and markets human therapeutics. 

**Performance Summary:**

**1. Performance vs. S&P 500:**

* **Cumulative Return:** Amgen's cumulative return stands at 89.06% while the S&P 500 (VOO) has yielded 132.53%. This represents a **-43.47% underperformance** compared to the benchmark.
* **Relative Outperformance:** The current relative outperformance is at 42.31%, meaning Amgen's performance is currently in the 42.31st percentile compared to its historical performance relative to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $337.38
* **5-Day Moving Average:** $334.73
* **20-Day Moving Average:** $330.19
* **60-Day Moving Average:** $326.95
* **Analysis:** The stock price is currently trading above all three moving averages, indicating potential positive momentum.

**3. Technical Indicators:**

* **RSI:** 54.82 (Neutral) - The RSI suggests the stock is currently in neutral territory, neither overbought nor oversold.
* **PPO:** 0.23 (Slight Bullish) - The PPO indicates a slight bullish sentiment. 
* **Delta_Previous_Relative_Divergence:** 1.69 (Positive) - The positive value suggests a potential short-term upward trend.
* **Expected_Return:** 9.0% - The expected return represents the potential maximum 5-year return on investment based on current market conditions.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue | 
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ | **(Actual)** 
| 2024-05-03 | -0.21 | 7.45 B$ | **(Actual)**
| 2023-10-31 | 3.23 | 6.90 B$ | **(Actual)** 
| 2023-08-04 | 2.58 | 6.99 B$ | **(Actual)** 
| 2024-08-07 | 2.58 | 6.99 B$ | **(Actual)** 

* **Most Recent Earnings:** Amgen exceeded analysts' expectations for the quarter ending August 7, 2024, reporting EPS of $1.39 against an estimated $1.14. Revenue also surpassed expectations, reaching $8.39 billion versus an anticipated $8.17 billion.  

**5. Overall Analysis:**

Amgen has shown positive momentum in the recent period with its share price trading above its moving averages and positive technical indicators. While it has underperformed the S&P 500 in the long term, its recent earnings results indicate strength in the business. The positive Delta_Previous_Relative_Divergence suggests a short-term upward trend, further strengthening the bullish outlook. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research, consideration of individual financial circumstances and consultation with a qualified financial advisor. 
